What happened with ATEC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Alphatec Holdings supplies products that help surgeons plan and perform operations for spine disorders. Revenue comes mainly from spinal implants and medical imaging equipment and related services, with most sales in the United States. Its EOS X-ray systems support surgical planning and postoperative assessment. Its flagship Prone TransPsoas (PTP) approach lets surgeons work from the side and back while the patient remains face down, integrating SafeOp monitoring to provide real-time information about nerves.
Surgeons generally choose which products to use, but hospitals and surgical centers buy them and receive Alphatec’s invoices. Independent sales agents and employee sales representatives connect the company with these buyers. Sales depend on surgeons adopting its products and using them in procedures.
Hospitals’ ability to obtain payment from private insurers, Medicare and Medicaid substantially affects product demand and pricing; these payers do not pay Alphatec directly. The company also depends on outside manufacturers for its implants, instruments and imaging equipment. New devices and certain product changes cannot be marketed until the required regulatory clearance or approval is obtained.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Globus Medical challenges Alphatec across the same spine procedures, competing in implants, nerve monitoring, imaging and surgical robotics. Watch its new products in these areas for changes in the alternatives available to hospitals buying Alphatec’s implants and imaging equipment.
Orthofix Medical competes with Alphatec for spine surgeons’ choices and hospital purchases of implants, biologic materials and technology supporting surgery. Its Global Spine business accounted for 84% of total net sales in 2025, making that revenue line more relevant to Alphatec than its limb reconstruction business.
Carlsmed competes for surgeons’ adoption with personalized implants placed between vertebrae and surgical planning software, against Alphatec’s interbody implants and planning-enabled procedures. It sells its aprevo products to hospitals and ambulatory surgical centers; watch growth in surgeon users and use by existing users, the drivers it identifies for revenue growth.
SI-BONE competes with Alphatec in implants for sacroiliac fusion and pelvic fixation during spinal fusion, but covers a narrower range of procedures. Its news on those two uses is more relevant to Alphatec than developments in its pelvic trauma products.
Xtant Medical competes with Alphatec for hospitals’ spinal fusion purchases, selling implants that hold the spine in place and biologic materials used in these procedures. Focus on its spinal fixation products and spine-related biologics, rather than biologics sold for wound care or other procedures.
Medtronic’s Sofamor Danek spine business is a major rival for Alphatec’s hospital implant sales and surgeon relationships, though Medtronic’s overall business is much broader. Watch its spinal implant introductions rather than diabetes products for news that bears on Alphatec’s competitive position.
Johnson & Johnson’s DePuy Spine competes directly with Alphatec for hospitals’ spinal implant purchases, although spine is a small part of Johnson & Johnson’s overall business. Its spinal implant launches are the news to watch for Alphatec, rather than results from its prescription medicines.
Fed Interest Rate Decision
For Alphatec, the Fed’s decision on short-term interest rates matters because higher rates can lift interest paid on its SOFR-linked Braidwell loan, while lower rates can ease that cost and leave more earnings after interest.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates above expectations, higher rates can feed through to Alphatec’s SOFR-linked loan and raise interest expense, leaving less earnings after interest.
If it comes in below expectations
If the Fed sets rates below expectations, lower rates can ease interest costs on Alphatec’s SOFR-linked loan, leaving more earnings after interest.
Alphatec Holdings, Inc. earningsThis company
Alphatec earns most of its revenue from spine-surgery implants and imaging equipment, and this report will show whether more surgeries and higher revenue per surgery are outpacing product costs.
Read surgical volume and revenue per surgery alongside the share of revenue spent on cost of sales. If both growth measures rise while that cost share holds steady or falls, more surgeons are using Alphatec’s products and each procedure brings in more, improving the economics of the implant business. If the cost share rises, product costs are eating into that growth.
GLOBUS MEDICAL INC earningsGMED
Globus Medical’s report will show how its spine implants, imaging and surgical technologies shape the alternatives hospitals consider alongside Alphatec’s products.
Watch for new products and signs of adoption in Globus Medical’s spine implants, nerve monitoring, imaging and surgical robotics. More launches that surgeons take up would give hospitals more alternatives in procedures where Globus and Alphatec compete, intensifying the contest for implant and imaging purchases. Few such developments would mean less new pressure from this rival, not proof that Alphatec is selling more.
